We are pleased to share that today we have initiated patient dosing in a Phase 1/2 study of AT-1965 a CMTR2 inhibitor in patients with solid tumors. A huge thank you to the many people who dedicated countless hours to help bring AT-1965 into clinic trials.
Alyssum Therapeutics
Biotechnology Research
Alyssum Therapeutics is a biotechnology company which is developing next-generation immunotherapies to modulate B cells
About us
Alyssum Therapeutics, a biotechnology company which is developing next-generation immunotherapies to modulate B cells
- Website
-
www.alyssumtx.com
External link for Alyssum Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2018